Bristol Pays Out $200m For Agenus' Preclinical Bispecific TIGIT
Agenus president Jennifer Buell talked to Scrip about partnering with Bristol and the dual nature approach of AGEN1777.

Agenus president Jennifer Buell talked to Scrip about partnering with Bristol and the dual nature approach of AGEN1777.